{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:20:25Z","timestamp":1790893225505,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.medcli.2024.06.012","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T15:50:25Z","timestamp":1724341825000},"page":"490-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of disease-modifying antirheumatic drugs in primary Sj\u00f6gren's syndrome-related interstitial lung disease"],"prefix":"10.1016","volume":"163","author":[{"given":"Funda","family":"Erbasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir Sayg\u0131n","family":"\u00d6\u011f\u00fct","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melis","family":"Dilbil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Nokay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Ender","family":"Terzio\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli","family":"Yaz\u0131s\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.06.012_bib0170","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.06.012_bib0175","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.06.012_bib0180","doi-asserted-by":"crossref","first-page":"102447","DOI":"10.1016\/j.autrev.2019.102447","article-title":"Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sj\u00f6gren's syndrome: a systematic review from the Italian Society of Rheumatology","volume":"19","author":"Sambataro","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.medcli.2024.06.012_bib0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2016.09.017","article-title":"Interstitial lung disease in primary Sj\u00f6gren's syndrome","volume":"16","author":"Roca","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.medcli.2024.06.012_bib0190","article-title":"Prognostic factors in interstitial lung disease associated with primary Sj\u00f6gren's syndrome: a retrospective analysis of 33 pathologically-proven cases","volume":"9","author":"Enomoto","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.medcli.2024.06.012_bib0195","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1164\/rccm.200403-417OC","article-title":"Pulmonary manifestations of primary Sj\u00f6gren's syndrome: a clinical, radiologic, and pathologic study","volume":"171","author":"Ito","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. 126","key":"10.1016\/j.medcli.2024.06.012_bib0200","first-page":"291","article-title":"Interstitial lung disease in Sj\u00f6gren's syndrome: a clinical review","volume":"38","author":"Luppi","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"Pt 1","key":"10.1016\/j.medcli.2024.06.012_bib0205","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1164\/ajrccm.154.3.8810621","article-title":"Interstitial lung disease in primary Sj\u00f6gren's syndrome. Clinical\u2013pathological evaluation and response to treatment","volume":"154","author":"Deheinzelin","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medcli.2024.06.012_bib0210","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sj\u00f6gren's syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2024.06.012_bib0215","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.medcli.2024.06.012_bib0220","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2024.06.012_bib0225","first-page":"136","article-title":"Treatment of primary Sj\u00f6gren's syndrome-related interstitial lung disease: a retrospective cohort study","volume":"37","author":"Amlani","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.medcli.2024.06.012_bib0230","doi-asserted-by":"crossref","first-page":"483","DOI":"10.55563\/clinexprheumatol\/o5t1f7","article-title":"Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease","volume":"40","author":"Benad","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.medcli.2024.06.012_bib0235","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.06.012_bib0240","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/0961203314546023","article-title":"Rituximab in primary Sj\u00f6gren's syndrome: a ten-year journey","volume":"23","author":"Carubbi","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.medcli.2024.06.012_bib0245","first-page":"1077","article-title":"Rituximab therapy in primary Sj\u00f6gren's syndrome with interstitial lung disease: a retrospective cohort study","volume":"34","author":"Chen","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.medcli.2024.06.012_bib0250","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.06.012_bib0255","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","article-title":"American College of Rheumatology classification criteria for Sj\u00f6gren's syndrome: a data-driven, expert consensus approach in the Sj\u00f6gren's International Collaborative Clinical Alliance cohort","volume":"64","author":"Shiboski","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.medcli.2024.06.012_bib0260","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.06.012_bib0265","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"15","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medcli.2024.06.012_bib0270","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12890-022-01868-5","article-title":"Interstitial lung disease in Primary Sj\u00f6gren's syndrome","volume":"27","author":"Lin","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.medcli.2024.06.012_bib0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.06.012_bib0280","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.chest.2020.10.011","article-title":"Consensus guidelines for evaluation and management of pulmonary disease in Sj\u00f6gren's","volume":"159","author":"Lee","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.medcli.2024.06.012_bib0285","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"22","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.06.012_bib0290","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.autrev.2020.102742","article-title":"Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development","volume":"20","author":"Karakontaki","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.medcli.2024.06.012_bib0295","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000214841","article-title":"Pulmonary manifestations of Sj\u00f6gren's syndrome","volume":"78","author":"Shi","year":"2009","journal-title":"Respiration"},{"key":"10.1016\/j.medcli.2024.06.012_bib0300","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s42358-021-00170-y","article-title":"Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis","volume":"27","author":"de Figueiredo Caldas","year":"2021","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.medcli.2024.06.012_bib0305","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2024.06.012_bib0310","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren's syndrome after two infusions of rituximab (anti-CD20)","volume":"15","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2024.06.012_bib0315","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.41085","article-title":"Using transitional changes on high-resolution computed tomography to monitor the impact of cyclophosphamide or mycophenolate mofetil on systemic sclerosis-related interstitial lung disease","volume":"72","author":"Kim","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.medcli.2024.06.012_bib0320","doi-asserted-by":"crossref","first-page":"12827","DOI":"10.1038\/s41598-021-92024-2","article-title":"Long-term clinical course and outcome in patients with primary Sj\u00f6gren syndrome-associated interstitial lung disease","volume":"18","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.medcli.2024.06.012_bib0325","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s10067-019-04906-6","article-title":"Characteristics of patients with primary Sj\u00f6gren's syndrome associated interstitial lung disease and relevant features of disease progression","volume":"39","author":"Zhang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2024.06.012_bib0330","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fmed.2020.00332","article-title":"Lung involvement in primary Sj\u00f6gren's syndrome \u2013 an under-diagnosed entity","volume":"16","author":"Sogkas","year":"2020","journal-title":"Front Med (Lausanne)"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324004755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324004755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T02:31:57Z","timestamp":1731724317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775324004755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0025775324004755"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.06.012","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of disease-modifying antirheumatic drugs in primary Sj\u00f6gren's syndrome-related interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}